News & Views - Page 45 of 53 - Telix Pharmaceuticals Limited

Telix to Present at European Association of Nuclear Medicine 2020 Annual Congress

Telix sponsored a session at the recent EANM20 Satellite Symposium, entitled “Next Generation Imaging with PSMA-PET & More”. For those unable to attend, we are pleased to provide recordings of live presentations held on 29th October 2020.

Telix Pharmaceuticals to Participate at AusBiotech + Invest 2020

Telix Pharmaceuticals is pleased to announce we are participating at AusBiotech + Invest 2020 online conference to be held live 28th – 30th October 2020 and on-demand. Telix is pleased to be sponsoring the “Radiopharmaceuticals drug development: current and future trends” session on Thursday 29th October 2.15 pm – 3.00 pm (AEST).

Telix Granted FDA Orphan Drug Designation for Glioma Imaging Agent

Telix Pannounces FDA has granted Orphan Drug Designation (ODD) for O-(2-[18F]fluoroethyl)-L-tyrosine for PET imaging of glioma

Telix Pharmaceuticals Submits New Drug Application to US FDA for Prostate Cancer Imaging Product

Telix Pharmaceuticals submits NDA to US FDA for TLX591-CDx (Kit for the preparation of 68Ga-PSMA-11)

First Patients Dosed in Clinical Trial of Novel Lung and Ovarian Cancer Theranostic

Telix announces first two patients dosed in phase I trial of lung & ovarian cancer theranostic

Telix Pharmaceuticals Enters Strategic Collaboration with Varian Medical Systems for Advanced Prostate Imaging

Telix announces it has entered into a strategic collaboration agreement with Varian Medical Systems

Telix Pharmaceuticals and IRE Elit Enter Distribution Partnership for Prostate Cancer Imaging

Telix announces distribution agreement with Fleurus-based IRE Elit S.A. to distribute Telix’s prostate cancer imaging product

FDA Grants Orphan Drug Designation for TLX102

Telix announces the FDA has granted ODD for 4-[211At] astato-l-phenylalanine for the treatment of multiple myeloma.

First Patient Dosed in Renal Cancer Imaging Study in Japan

Telix announces the first patient has been dosed in a Phase I/II study of Telix’s renal cancer diagnostic imaging product TLX250-CDx in Japan

Telix H1 2020 Results and Company Update Conference Call

Telix will hold an investor conference call to present the Company’s H1 2020 financial results together with an update on Telix’s operations.